Science Explorer Back to mapMap

Most cited papers from Dallas Diabetes Research Center

What are the most cited papers from Dallas Diabetes Research Center?

The most cited paper from Dallas Diabetes Research Center is "Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes" (Steven P. Marso, Stephen Charles Bain, Agostino Consoli et al., 2016), with 6,902 citations. Next come "Once-Weekly Semaglutide in Adults with Overweight or Obesity" (5,049) and "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes" (2,029).

Showing 50 of 60 papers. Every paper with more than 259 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes Steven P. Marso, Stephen Charles Bain, Agostino Consoli et al. · New England Journal of Medicine Open access 16 Sep 2016 6,902
2 Once-Weekly Semaglutide in Adults with Overweight or Obesity John P.H. Wilding, Rachel Louise Batterham, Salvatore Calanna et al. · New England Journal of Medicine Open access 10 Feb 2021 5,049
3 Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Juan P. Frías, Melanie J. Davies, Julio Rosenstock et al. · New England Journal of Medicine Open access 25 Jun 2021 2,029
4 Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Naveed A. Sattar, Matthew M.Y. Lee, Søren Lund Kristensen et al. · The Lancet Diabetes & Endocrinology ReviewOpen access 20 Aug 2021 1,590
5 Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) John B. Buse, Julio Rosenstock, Giorgio Sesti et al. · The Lancet 9 Jun 2009 1,505
6 The Treat-to-Target Trial Matthew C. Riddle, Julio Rosenstock, John Gerich et al. · Diabetes Care Open access Nov 2003 1,482
7 Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial Melanie J. Davies, Louise Færch, Ole Kleist Jeppesen et al. · The Lancet Open access Mar 2021 1,384
8 Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity Domenica Rubino et al. · JAMA Open access 23 Mar 2021 1,377
9 Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea David M. Kendall, Matthew C. Riddle, Julio Rosenstock et al. · Diabetes Care May 2005 1,180
10 Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk Julio Rosenstock, Vlado Perkovic, Odd Erik Johansen et al. · JAMA Open access 12 Nov 2018 1,099
11 Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension John P.H. Wilding, Rachel Louise Batterham, Melanie J. Davies et al. · Diabetes Obesity and Metabolism Open access 19 Apr 2022 1,066
12 Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Julio Rosenstock, Carol Wysham, Juan P. Frías et al. · The Lancet 27 Jun 2021 1,057
13 Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes Domenica M. Rubino et al. · JAMA Open access 11 Jan 2022 937
14 Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study on behalf of the NN8022-1923 Investigators, Thomas A. Wadden, Priscilla A. Hollander et al. · International Journal of Obesity Jul 2013 833
15 Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes Hertzel C. Gerstein, Naveed A. Sattar, Julio Rosenstock et al. · New England Journal of Medicine Open access 28 Jun 2021 824
16 Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial Julio Rosenstock, Michael M. Tuchman, Linda LaMoreaux et al. · Pain 16 Jun 2004 730
17 NEW-ONSET DIABETES AFTER TRANSPLANTATION: 2003 INTERNATIONAL CONSENSUS GUIDELINES1 Jaime A. Davidson, Alan H. Wilkinson, Jacques Dantal et al. · Transplantation May 2003 679
18 Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors Julio Rosenstock, Ele Ferrannini · Diabetes Care 10 Aug 2015 666
19 Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes Julio Rosenstock, Steven E. Kahn, Odd Erik Johansen et al. · JAMA Open access 19 Sep 2019 617
20 METABOLIC COUPLING FACTORS IN PANCREATIC β-CELL SIGNAL TRANSDUCTION Christopher B. Newgard, Julie McGarry · Annual Review of Biochemistry Jun 1995 532
21 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Julio Rosenstock, Ronald Brazg, Paula J. Andryuk et al. · Clinical Therapeutics Oct 2006 516
22 Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes John B. Buse, Richard M. Bergenstal, Leonard C. Glass et al. · Annals of Internal Medicine 18 Jan 2011 508
23 Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes Melanie J. Davies, Thomas Rudolf Pieber, Marie‐Louise Hartoft‐Nielsen et al. · JAMA Open access 17 Oct 2017 498
24 PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes Vanita R. Aroda et al. · Diabetes Care Open access105 authors 11 Jun 2019 485
25 Basal Insulin Therapy in Type 2 Diabetes Julio Rosenstock, Sherwyn Leon Schwartz, Charles M. Clark et al. · Diabetes Care Open access Apr 2001 482
26 Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea Guntram Schernthaner, Jorge Luiz Gross, Julio Rosenstock et al. · Diabetes Care Open access 6 Apr 2013 482
27 Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial Helena W. Rodbard et al. · Diabetes Care Open access118 authors 17 Sep 2019 464
28 A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes Julio Rosenstock, Melanie J. Davies, Philip Home et al. · Diabetologia Open access 15 Jan 2008 448
29 Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes Julio Rosenstock, Naresh Aggarwal, David Polidori et al. · Diabetes Care Open access 10 Apr 2012 423
30 Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea Julio Rosenstock, Dale Allison, Andreas L. Birkenfeld et al. · JAMA Open access 23 Mar 2019 414
31 Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy Julio Rosenstock, Marisa L. Vico, Wei Li et al. · Diabetes Care Open access 24 Mar 2012 408
32 Lipoapoptosis in Beta-cells of Obese Prediabeticfa/fa Rats Michio Shimabukuro, Moritake Higa, Yan-Ting Zhou et al. · Journal of Biological Chemistry Open access Dec 1998 395
33 Diabetes and breast cancer risk: a meta-analysis Peter A. Boyle, Mathieu Boniol, Alice Koechlin et al. · British Journal of Cancer ReviewOpen access 20 Sep 2012 381
34 Essentiality of circulating fatty acids for glucose-stimulated insulin secretion in the fasted rat. Daniel T. Stein, Victoria Esser, Brent E Stevenson et al. · Journal of Clinical Investigation Open access 15 Jun 1996 379
35 Reduced Hypoglycemia Risk With Insulin Glargine Julio Rosenstock, GEORGE E. DAILEY, Massimo Massi‐Benedetti et al. · Diabetes Care Apr 2005 372
36 Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From aDiabetes CareEditors’ Expert Forum William T. Cefalu, Sanjay Kaul, Hertzel C. Gerstein et al. · Diabetes Care Open access 20 Dec 2017 370
37 Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes Julio Rosenstock, Ante Jelaska, Guillaume Frappin et al. · Diabetes Care Open access 12 Jun 2014 368
38 Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials Julio Rosenstock, Jan Marquard, Lori M. Laffel et al. · Diabetes Care 4 Oct 2018 364
39 A Randomized Trial of Rosiglitazone Therapy in Patients With Inadequately Controlled Insulin-Treated Type 2 Diabetes Philip Raskin, Marc Rendell, Matthew C. Riddle et al. · Diabetes Care Jul 2001 346
40 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial Baptist Gallwitz, Julio Rosenstock, Thomas Rauch et al. · The Lancet 27 Jun 2012 343
41 The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies John B. Buse, Ralph Anthony DeFronzo, Julio Rosenstock et al. · Diabetes Care 18 Aug 2015 330
42 Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study Richard E. Pratley, Michael Albrecht Nauck, Anthony H Barnett et al. · The Lancet Diabetes & Endocrinology 5 Feb 2014 327
43 Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial Alan J. Garber, Allen Bennett King, Stefano Del Prato et al. · The Lancet Apr 2012 326
44 Set points, settling points and some alternative models: theoretical options to understand how genes and environments combine to regulate body adiposity John Roger Speakman et al. · Disease Models & Mechanisms Open access Nov 2011 323
45 The 11-β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor INCB13739 Improves Hyperglycemia in Patients With Type 2 Diabetes Inadequately Controlled by Metformin Monotherapy Julio Rosenstock, Salomon Banarer, Vivian Andrew Fonseca et al. · Diabetes Care Open access 22 Apr 2010 318
46 Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes Tina Vilsbøll, Julio Rosenstock, Hannele Yki-Järvinen et al. · Diabetes Obesity and Metabolism Open access 6 Nov 2009 305
47 Obesity, Diabetes, and Increased Cancer Progression Dae-Seok Kim, Philipp E. Scherer · Diabetes & Metabolism Journal Open access 22 Nov 2021 302
48 Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study Marja‐Riitta Taskinen, Julio Rosenstock, Ilkka Tamminen et al. · Diabetes Obesity and Metabolism 18 Oct 2010 294
49 Dual Add-on Therapy in Type 2 Diabetes Poorly Controlled With Metformin Monotherapy: A Randomized Double-Blind Trial of Saxagliptin Plus Dapagliflozin Addition Versus Single Addition of Saxagliptin or Dapagliflozin to Metformin Julio Rosenstock, Lars Lindgaard Hansen, Pamela Zee et al. · Diabetes Care 28 Oct 2014 290
50 Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin Matthew C. Riddle, Ronnie Aronson, Philip Home et al. · Diabetes Care Open access 30 Apr 2013 289

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.